Telomerase and telomere length in multiple myeloma: Correlations with disease heterogeneity, cytogenetic status, and overall survival

Blood

Volumn 101, Issue 12, 2003, Pages 4982-4989

  Wu, Kai Da ^b   Orme, Lisa M ^b   Shaughnessy Jr , John ^b   Jacobson, Joth ^b   Barlogie, Bart ^b   Moore, Malcolm A S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; INTERLEUKIN 6; TELOMERASE;

ADULT; AGE; AGED; ANALYTIC METHOD; ARTICLE; BONE MARROW; BONE MARROW CELL; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CELL ISOLATION; CHROMOSOME ANALYSIS; CHROMOSOME SIZE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; LEUKOCYTE; MULTIPLE MYELOMA; NEUROBLASTOMA CELL; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TELOMERE; THROMBOCYTE COUNT;

EID: 0038235696     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3451     Document Type: Article

References (60)

1. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet. 2001;10:677-685.
2. Stewart SA, Weinberg RA, Telomerase and human tumorigenesis. Semin Cancer Biol. 2000;10:399-406.
3. Hackett JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene. 2002;21:619-626.
4. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene. 2002;21:598-610.
5. Elenbaas B, Spiro L, Koerner F, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001;15:50-65.
6. Lundberg AS, Randell SH, Stewart SA, et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene. 2002;21:4577-4586.
7. MacKenzie KL, Franco S, Naiyer AJ, et a. Multiple stages of malignant transformation of human endothelial cells modeled by co-expression of telomerase reverse transcriptase, SV40 large T antigen and oncogenic N-ras. Oncogene. 2002;21:4200-4211.
8. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol. 2001;19:114-120.
9. Kim MM, Rivera MA, Botchkina IL, Shalaby R, Thor AD, Blackburn EH. A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc Natl Acad Sci U S A. 2001;98:7982-7987.
10. Boklan J, Nanjangud G, MacKenzie KL, May C, Sadelain M, Moore MAS. Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts. Cancer Res. 2002;62:2104-2114.
11. Granger MP, Wright WE, Shay JW. Telomerase in cancer and aging. Crit Rev Oncol Hematol. 2002 41:29-40.
12. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci U S A. 1994;91:2900-2904.
13. Hiyama E, Gollahon L, Kataoka T, et al. Telomerase activity in human breast tumors. J Natl Cancer Inst. 1996;2;88:116-122.
14. Engelhardt M, Albanell J, Drullinsky P, et al. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma. Clin Cancer Res. 1997a;3:1849-1857.
15. Engelhardt M, Drullinsky P, Guillem J, Moore MAS. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res. 1997b;3:1931-1941.
16. Albanell J, Lonardo F, Rusch V, et al. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst. 1997;89:1609-1615.
17. Hiraga S, Ohnishi T, Izumoto S, et al. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res. 1998;58:2117-2125.
18. Bednarek AK, Sahin A, Brenner AJ, Johnston DA, Aldaz CM. Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage. Clin Cancer Res. 1997;3:11-16.
19. Engelhardt M, MacKenzie K, Drullinsky P, Silver RT, Moore MAS. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res. 2000;60:610-617.
20. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene. 2002;21:680-687.
21. Brummendorf TH, Holyoake TL, Rufer N, et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood. 2000;95:1883-1890.
22. Norrback K-F, Dahlenborg K, Carlsson R, Roos G, Telomerase activation in normal B lymphocytes and non-Hodgin's lymphomas. Blood. 1996;88:222-229.
23. Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4918-4922.
24. Trentin L, Ballon G, Ometto L, et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol. 1999;106:662-668.
25. Ely SA, Chadburn A, Dayton CM, Cesarman E, Knowles DM. Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer. 2000;89:445-452.
26. Wu K, Lund M, Bang K, Thestrup-Pedersen K. Telomerase activity and telomere length in lymphocytes from patients with cutaneous T-cell lymphoma. Cancer. 1999;86:1056-1063.
27. Xu D, Zheng C, Bergenbrant S, et al. Telomerase activity in plasma cell dyscrasias. Br J Cancer. 2001;84:621-625.
28. Shiratsuchi M, Muta K, Abe Y, et al. Ctinical significance of telomerase activity in multiple myeloma. Cancer. 2002;94:2232-2238.
29. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
30. Smith S, de Lange T. Tankyrase promotes telomere elongation in human cells. Curr Biol. 2000;10:1299-1302.
31. Blackburn EH. Switching and signaling at the telomere. Cell. 2001;106:661-673.
32. Liu K, Hodes RJ, Weng N. Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J Immunol. 2001;166:4826-4830.
33. Akiyama M, Hideshima T, Hayashi T, et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002;62:3876-3882.
34. Wu K, Higashi N, Hansen ER, Lund M, Bang K, Thestrup-Pedersen K. Telomerase activity is increased and telomere length shortened in T cells from blood of patients with atopic dermatitis and psoriasis. J Immunol. 2000;165:4742-4747.
35. Ouellette MM, Liao M, Herbert B-S, et al. Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase. J Biol Chem. 2000;275:10072-10076.
36. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
37. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
38. Zhu J, Wang H, Bishop JM, Blackburn EH. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci U S A. 1999;96:3723-3728.
39. Steinert S, Shay JW, Wright WE. Transient expression of human telomerase extends the lifespan of normal human fibroblasts. Biochem Biophys Res Commun. 2000;273:1095-1098.
40. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80:733-737.
41. Engelhardt M, Kumar R, Albanell J, Pettengeli R, Han W, Moore MAS. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood. 1997;90:182-193.
42. Zhu X, Kumar R, Mandal M, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci U S A. 1996;93:6091-6095.
43. Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000;96:1505-1511.
44. Karlseseder J, Smorgorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. Science. 2002;295:2446-2449.
45. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J. Gene expression profiling of normal human plasma cell differentiation and the classification of multiple myeloma based on similarities to distinct stages of late stage B-cell development. Blood. 2003;101:1128-1140.
46. Weng NP, Granger L, Hodes RJ. Telomere lengthening and telomerase activation during human B cell differentiation. Proc Natl Acad Sci U S A. 1997;94:10827-10832.
47. Hu BT, Lee SC, Marin E, Ryan DH, Insel RA. Telomerase is upregulated in human germinal cells in vivo and can be re-expressed in memory B cells activated in vitro. J Immunol. 1997;159:1068-1071.
48. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene. 2002;21:598-610.
49. Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet. 2001;10:1945-1952.
50. Herrera E, Martinez C, Blasco MA. Impaired germinal center reaction in mice with short telomeres. EMBO J. 2000;19:472-481.
51. Yeager TR, Neumann AA, Englezou A, et al. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 1999;59:4175-4179.
52. Drach J, Ayers D, Govindarajan R, et al. MDS-associated cytogenetic abnormalities in both hematopoietic and neoplastic cells after auto transplantation in 868 patients with multiple myeloma [abstract]. Blood. 1998;92:97.
53. Klausner RD. The fabric of cancer cell biology - weaving together the strands. Cancer Cell. 2002;1:3-10.
54. Lee H-W, Blasco MA, Gottlieb GJ, Horner JW, Greider CW, Depinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature. 1998;392:569-574.
55. Tanaka H, Shimizu M, Horikawa I, et al. Evidence for a putative telomerase repressor gene in the 3p14.2-p21. 1 region. Genes Chromosomes Cancer. 1998;23:123-133.
56. Horikawa I, Oshimura M, Barrett CJ. Repression of the telomerase catalytic subunit by a gene on chromosome 3 that induces cellular senescence. Mol Carcinog. 1998;22:65-72.
57. Cuthbert AP, Bond J, Trott DA, et al. Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. J Natl Cancer Inst. 1999;91:37-45.
58. Ducrest A-L, Amacker M, Mathieu YD, et al. Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase but does not affect c-Myc activity. Cancer Res. 2001;61:7594-7602.
59. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentric heterochromatin. Blood. 1998;91:1732-1741.
60. Hatakeyama S, Fujita K, Mori H, Omine M, Ishikawa F. Shortened telomeres involved in a case with a jumping translocation at 1q21. Blood. 1998;91:1514-1519.